Skip to content
Open access

Modeling of ex vivo immune response reveals a central role for CD8+CD25+ cells in Adult T-cell Leukemia survival: a long-term prospective cohort study

Aug 2026 · Tumour Virus Research · Vol 22, pp. 200349 · 0 citations · 48 references
Medicine

TL;DR

Ex vivo data mining allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival and HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.

Abstract

Adult T-cell leukemia (ATL) is a rare but aggressive CD4+CD25+ leukemia triggered by HTLV-1 infection. We quantified ex vivo levels of CD4+ and CD8+ (sub)populations and their antiproliferative, pro-apoptotic, antiviral and immunomodulatory interplay in short-term culture of primary cells from ATL patients, in a long-term prospective study (819 person-years of follow-up). We integrated clinical, cellular and molecular data into a data mining approach combining linear (consensus HIerarchical Tree clustering) and non-linear (BAYesian network) models. This HIT-BAY approach revealed an association between CD8+CD25+ cells and survival, independent of CD4+CD25+ cells. Moreover, CD8+CD25+ levels at diagnosis significantly predicted 5-year survival in ATL patients (p = 0.037), which was confirmed in multivariable Cox regression models correcting for clinical forms. We provide in vivo support for our ex vivo model in a unique patient on AZT monotherapy, for whom adding IFN-α resulted in a rapid (<2 weeks) and pronounced (>70%) decline in leukemic/non-leukemic cell ratio, accompanied by a ten-fold increase CD8+CD25+ levels, and followed by long-term survival. Finally, transcriptomic analysis of a CD8+CD25+ gene module and replication in an independent ATL cohort revealed shared cytotoxic activity of both CD8+CD25+ and Tax-specific CD8+ cells as an underlying mechanism for prolonged survival. In conclusion, our integrated data mining approach allowed us to integrate ex vivo clinical and immunological data, revealing a central role for CD8+CD25+ cells in ATL survival. HIT-BAY might serve as a prototype to model immune response and facilitate biomarker and therapeutic target discovery in real-world cohorts, including rare malignancies.

Read PDF

Similar papers

Open access Oct 2026

A CD68-expressing tissue-homing subset in peripheral CD8+ T cells predicts response to anti-PD-1 therapy in lung cancer

Background T-cell function is regulated by immunometabolism, and lysosomes are signaling hubs. CD68 (LAMP4), traditionally regarded as a monocyte/macrophage marker, has been largely neglected in T cell biology. We aimed to assess the link between CD68 expression in T cells and anti-PD-1 response in lung cancer, and its...

Ying Wang, Jing Huang, Zheng-Yi Sun et al. · 0 citations
Open access Oct 2026

Distinct cellular dynamics following CD19 and CD7 CAR-T therapies revealed by high-dimensional CyTOF analysis and impact on clinical outcomes

Compared with CD19 CAR-T therapy, CD7 CAR-T therapy was characterized by reduced CD8+ CAR-T persistence, early exhaustion, and delayed immune reconstitution, correlating with increased infections and higher non-relapse mortality.

Zhi-Peng Zhou, Yi-Yang Ding, Zhuo-Jun Liu et al. · 0 citations
Open access Oct 2026

Peripheral CD4+ T-Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor-Associated Immune Modulation in B-Cell Lymphoma.

Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B-cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively evaluated associations between peripheral immune profiles and outcomes in 40 patient...

Hui Yu, Jin Chai, Jiao-Wu Cao et al. · 0 citations
Oct 2026

Genetic and clinical evidence supports HLA-DR+ CD8+ T cells as a favorable immune biomarker in acute myeloid leukemia.

Immune dysregulation is central to acute myeloid leukemia (AML), but the contribution of specific immune subsets remains uncertain. We combined Mendelian randomization (MR), clinical flow cytometry, and transcriptomic profiling to investigate HLA-DR+ CD8+ T cells in AML. Two-sample MR using 731 immunophenotypes and AML...

Gang Chen, Jing Xu, Xiao-Yu He et al. · 0 citations
Open access Sep 2026

A Single-Cell-Derived CD8+ T-Cell State Plasticity Score for Prognostic Stratification and Characterization of Immune Responsiveness in Hepatocellular Carcinoma

Background T cells play a central role in antitumor immunity. Emerging evidence indicates that T-cell plasticity and differentiation states are associated with clinical outcomes and responses to cancer immunotherapy. CD8⁺ T cells that retain differentiation potential are thought to sustain effective antitumor immunity....

Le Xing, Dan He, Dong-Mei Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.